Talsupram hydrochlorideSelective inhibitor of noradrenalin transporters CAS# 25487-28-9 |
- SB-222200
Catalog No.:BCC1926
CAS No.:174635-69-9
- Talnetant hydrochloride
Catalog No.:BCC1982
CAS No.:204519-66-4
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 25487-28-9 | SDF | Download SDF |
PubChem ID | 33013 | Appearance | Powder |
Formula | C20H26ClNS | M.Wt | 347.95 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | Soluble to 20 mM in water and to 100 mM in DMSO | ||
Chemical Name | 1,3-Dihydro-N,3,3-trimethyl-1-pheny | ||
SMILES | [Cl-].C[NH2+]CCCC1(SC(C)(C)c2ccccc12)c3ccccc3 | ||
Standard InChIKey | YMZCMCDSCRSIBS-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C20H25NS.ClH/c1-19(2)17-12-7-8-13-18(17)20(22-19,14-9-15-21-3)16-10-5-4-6-11-16;/h4-8,10-13,21H,9,14-15H2,1-3H3;1H | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Selective noradrenalin re-uptake inhibitor; exhibits a high affinity for the human noradrenalin transporter (NET) against SERT and DAT (IC50 values are 0.79, 850 and 9300 nM for inhibition of monoamine uptake by NET, SERT and DAT respectively). Antidepressant. |
Talsupram hydrochloride Dilution Calculator
Talsupram hydrochloride Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.874 mL | 14.3699 mL | 28.7398 mL | 57.4795 mL | 71.8494 mL |
5 mM | 0.5748 mL | 2.874 mL | 5.748 mL | 11.4959 mL | 14.3699 mL |
10 mM | 0.2874 mL | 1.437 mL | 2.874 mL | 5.748 mL | 7.1849 mL |
50 mM | 0.0575 mL | 0.2874 mL | 0.5748 mL | 1.1496 mL | 1.437 mL |
100 mM | 0.0287 mL | 0.1437 mL | 0.2874 mL | 0.5748 mL | 0.7185 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Emricasan
Catalog No.:BCC5367
CAS No.:254750-02-2
- 2-MPPA
Catalog No.:BCC7995
CAS No.:254737-29-6
- Demethyleneberberine
Catalog No.:BCN2829
CAS No.:25459-91-0
- H-Asn-OtBu
Catalog No.:BCC2877
CAS No.:25456-86-4
- H-D-Glu-OtBu
Catalog No.:BCC2938
CAS No.:25456-76-2
- Felbamate
Catalog No.:BCC4904
CAS No.:25451-15-4
- (+)-Afzelechin
Catalog No.:BCN5121
CAS No.:2545-00-8
- Dehydropitavastatin ethyl ester
Catalog No.:BCC8931
CAS No.:254452-91-0
- H-Cys(pMeOBzl)-OH
Catalog No.:BCC2909
CAS No.:2544-31-2
- Phellopterin
Catalog No.:BCN2637
CAS No.:2543-94-4
- Boc-ß-HoAsp(OBzl)-OH
Catalog No.:BCC3229
CAS No.:254101-10-5
- Morroniside
Catalog No.:BCN5009
CAS No.:25406-64-8
- Curryangine
Catalog No.:BCN7907
CAS No.:25488-37-3
- 2,3-Bis(3,4-dimethoxybenzyl)butyrolactone
Catalog No.:BCN1473
CAS No.:25488-59-9
- Kushenol W
Catalog No.:BCN3307
CAS No.:254886-76-5
- Kushenol X
Catalog No.:BCN3350
CAS No.:254886-77-6
- 4-Allyloxy-2-hydroxybenzophenone
Catalog No.:BCC8675
CAS No.:2549-87-3
- Tasquinimod
Catalog No.:BCC1987
CAS No.:254964-60-8
- 3-Epioleanolic acid
Catalog No.:BCN3050
CAS No.:25499-90-5
- 4-Phenylbutan-2-one
Catalog No.:BCN3808
CAS No.:2550-26-7
- 1-Acetyl-4-piperidinecarboxylic acid
Catalog No.:BCC8447
CAS No.:25503-90-6
- Bruceine B
Catalog No.:BCN7615
CAS No.:25514-29-8
- Bruceine C
Catalog No.:BCN8000
CAS No.:25514-30-1
- Bruceine A
Catalog No.:BCC5311
CAS No.:25514-31-2
Synthesis and biological evaluation of [11C]talopram and [11C]talsupram: candidate PET ligands for the norepinephrine transporter.[Pubmed:15246361]
Nucl Med Biol. 2004 Aug;31(6):705-18.
PET and SPECT ligands for the norepinephrine transporter (NET) will be important tools for studying the physiology, pathophysiology and pharmacology of the CNS noradrenergic system in vivo. A series of candidate NET ligands were synthesized and characterized in terms of their affinity for human monoamine transporters. The two most promising compounds, talopram and talsupram, were radiolabeled with carbon-11 and evaluated through biodistribution studies in rats and PET imaging studies in a rhesus monkey. Although both compounds displayed high affinity and selectivity for the human NET in vitro, these compounds did not enter the CNS in adequate amounts to be used in PET imaging studies.
Cocaine-like discriminative stimulus effects of heroin: modulation by selective monoamine transport inhibitors.[Pubmed:14985417]
J Pharmacol Exp Ther. 2004 Jul;310(1):342-8.
In previous studies, heroin was shown to engender cocaine-like discriminative stimulus (DS) effects; however, the mechanisms underlying the cocaine-like effects of heroin are unknown. The present study evaluated the extent to which the shared DS effects of heroin and cocaine involve common monoaminergic mechanisms of action. In squirrel monkeys discriminating cocaine (0.3 mg/kg) from saline, heroin engendered full or partial substitution for cocaine in three of four monkeys. Pretreatment with the selective dopamine transport inhibitor 1-(2-[bis(4-fluorophenyl)methoxy]ethyl)-4-(3-phenylpropyl)piperazine (GBR 12909) dose dependently enhanced the cocaine-like DS effects of heroin in these three monkeys as well as the DS effects of cocaine in all subjects. Neither talsupram, a noradrenergic transport inhibitor, nor prazosin, a noradrenergic antagonist selective for alpha-1 receptors, systematically altered the cocaine-like DS effects of heroin at doses that enhanced (talsupram) or attenuated (prazosin) the DS effects of cocaine. Pretreatment with the serotonin uptake inhibitor citalopram similarly failed to alter the cocaine-like DS effects of heroin at doses that attenuated the DS effects of cocaine. Altogether, these findings suggest that heroin shares DS effects with cocaine in a subset of monkeys, and these cocaine-like effects are mediated at least in part by enhanced dopaminergic activity. Unlike the DS effects of cocaine itself, however, the cocaine-like DS effects of heroin do not appear to involve either noradrenergic or serotonergic mechanisms.